Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial adequate vancomycin therapy for methicillin-resistant Staphylococcus infection
ChiCTR-TRC-13003563Phase 4Completed
- Sponsor
- ICU Department of Qilu Hospital of Shandong University
- Start
- Oct 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin in methicillin-resistant Staphylococcus aureus infection (MRSA) (2 arms), sponsored by ICU Department of Qilu Hospital of Shandong University. Primary endpoints: Serum drug concentration, Clinical outcome and 1 more. Started Oct 2013; status: completed.
02
Drugs
vancomycin
03
Conditions
methicillin-resistant Staphylococcus aureus infection (MRSA)
Beyond the preview
Go deeper on ChiCTR-TRC-13003563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003563.